Dai-ichi Life has invested JPY 500m ($4.6m) in Noile-Immune Biotech, a Japanese start-up that develops cancer immunotherapy.
Through this investment, the insurer hopes to provide capital support for Noile-Immune's initiatives, which are expected to extend how long cancer patients can continue to lead healthy lives.
Companies:Dai-ichi Life
Leads consortium alongside Soya Group, in first Swedish transaction
Also announces $10m debt financing deal with clean energy provider EDF Renewables
Floating-rate financing provided to Longacre Group for 2,021-unit affordable housing portfolio
Insurance Risk Data makes a pinpoint breakdown of UK market risk
JPI initiated currency swap transactions in October for bond holdings
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here